HomeSelumetinibSelumetinib + Anti Platelet Agents

Does Selumetinib Interact with Anti Platelet Agents?

Selumetinib and Anti Platelet Agents have a moderate drug interaction according to U.S. FDA drug labeling data. KOSELUGO capsules contain vitamin E; concomitant use may increase bleeding risk. Monitor for bleeding. The mechanism involves vitamin e-mediated increased bleeding risk. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Selumetinib Class
Kinase Inhibitor
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Selumetinib and Anti Platelet Agents occurs because vitamin e-mediated increased bleeding risk. Clinically, this means koselugo capsules contain vitamin e; concomitant use may increase bleeding risk. monitor for bleeding. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Selumetinib and your doctor is considering prescribing Anti Platelet Agents (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Selumetinib(Koselugo)+💊 Anti Platelet Agents

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Kinase Inhibitor
Drug B class
Source
NLP:selumetinib

What this means in plain English

KOSELUGO capsules contain vitamin E; concomitant use may increase bleeding risk. Monitor for bleeding.

What the FDA label says

"Vitamin E-mediated increased bleeding risk"

📖 Source: NLP:selumetinib

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Selumetinib and Anti Platelet Agents against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.